Akebia Therapeutics
(AKBA)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -26,567 | -17,985 | -51,925 | -52,539 | -38,050 |
| Depreciation Amortization | 18,785 | 9,375 | 41,846 | 28,223 | 18,816 |
| Accounts receivable | 9,525 | 12,670 | 994 | 17,692 | 20,712 |
| Other Working Capital | -28,790 | -15,147 | -20,727 | -4,521 | -315 |
| Other Operating Activity | -2,451 | -8,345 | 6,428 | -9,931 | -15,072 |
| Operating Cash Flow | $-29,498 | $-19,432 | $-23,384 | $-21,076 | $-13,909 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -29 | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $-29 | $0 | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 45,000 | 37,000 | N/A | N/A | N/A |
| Debt Repayment | -37,100 | -36,726 | -32,000 | -24,000 | -24,000 |
| Common Stock Issued | 18,965 | 18,951 | 6,794 | 84 | 34 |
| Other Financing Activity | -750 | -750 | 0 | 0 | 0 |
| Financing Cash Flow | $26,115 | $18,475 | $-25,206 | $-23,916 | $-23,966 |
| Beginning Cash Position | 44,579 | 44,579 | 93,169 | 93,169 | 93,169 |
| End Cash Position | 41,167 | 43,622 | 44,579 | 48,177 | 55,294 |
| Net Cash Flow | $-3,412 | $-957 | $-48,590 | $-44,992 | $-37,875 |
| Free Cash Flow | |||||
| Operating Cash Flow | -29,498 | -19,432 | -23,384 | -21,076 | -13,909 |
| Capital Expenditure | -29 | N/A | N/A | N/A | N/A |
| Free Cash Flow | -29,527 | -19,432 | -23,384 | -21,076 | -13,909 |